NANJING, China, April 15, 2025 /PRNewswire/ -- ProBio, a global leader in the antibody discovery and development, is pleased to announce its upcoming poster presentation at the American Association ...

Antengene Corporation Limited (Antengene), a leading innovative, commercial-stage global biotech company, and UCB, a global ...

Excalipoint Therapeutics will use its seed money to advance a pipeline of cancer therapies, including a tri-specific antibody for small cell lung cancer and neuroendocrine tumors.

A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...

Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...

Teplizumab has shown significant preservation of C-peptide levels in newly diagnosed type 1 diabetes (T1D) patients, indicating the potential for modifying disease progression. Combining teplizumab ...

Targeting the T-cell co-receptor cluster of differentiation 3 (CD3) in type 1 diabetes (T1D) mellitus may impede the autoimmune attack initiated by a triggering event, thus slowing or preventing ...